Morgan Stanley assumed coverage on shares of Cytokinetics, Incorporated (NASDAQ:CYTK) in a research report sent to investors on Monday, MarketBeat reports. The brokerage issued an overweight rating and a $24.00 target price on the biopharmaceutical company’s stock.

Other research analysts have also issued research reports about the stock. BidaskClub upgraded shares of Cytokinetics, from a sell rating to a hold rating in a research report on Thursday, July 13th. ValuEngine upgraded shares of Cytokinetics, from a sell rating to a hold rating in a research report on Friday, June 2nd. Zacks Investment Research lowered shares of Cytokinetics, from a buy rating to a sell rating in a research report on Monday, July 17th. Cantor Fitzgerald restated an overweight rating on shares of Cytokinetics, in a research report on Friday, May 19th. Finally, Cowen and Company restated an outperform rating and issued a $19.00 price target (up previously from $17.00) on shares of Cytokinetics, in a research report on Saturday, April 29th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of Buy and a consensus target price of $21.20.

Cytokinetics, (NASDAQ CYTK) traded down 3.33% during midday trading on Monday, reaching $13.05. The company had a trading volume of 196,341 shares. The company’s market capitalization is $629.23 million. The company’s 50 day moving average is $13.67 and its 200-day moving average is $12.95. Cytokinetics, has a 52-week low of $8.51 and a 52-week high of $17.20.

Cytokinetics, (NASDAQ:CYTK) last posted its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by $0.03. The business had revenue of $3.05 million during the quarter, compared to analyst estimates of $5.28 million. Cytokinetics, had a negative return on equity of 17.38% and a negative net margin of 16.00%. Equities analysts expect that Cytokinetics, will post ($2.02) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2017/08/04/cytokinetics-incorporated-cytk-research-coverage-started-at-morgan-stanley.html.

In related news, CEO Robert I. Blum sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $12.14, for a total value of $60,700.00. Following the completion of the transaction, the chief executive officer now owns 88,385 shares of the company’s stock, valued at approximately $1,072,993.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 15,000 shares of company stock valued at $197,750 in the last ninety days. Company insiders own 7.20% of the company’s stock.

A number of institutional investors have recently bought and sold shares of CYTK. State of Alaska Department of Revenue acquired a new stake in Cytokinetics, during the second quarter valued at about $109,000. Municipal Employees Retirement System of Michigan acquired a new stake in Cytokinetics, during the second quarter valued at about $132,000. LMR Partners LLP acquired a new stake in Cytokinetics, during the first quarter valued at about $156,000. Bank of America Corp DE boosted its stake in Cytokinetics, by 36.8% in the first quarter. Bank of America Corp DE now owns 12,571 shares of the biopharmaceutical company’s stock valued at $162,000 after buying an additional 3,383 shares during the period. Finally, BNP Paribas Arbitrage SA boosted its stake in Cytokinetics, by 4,464.4% in the second quarter. BNP Paribas Arbitrage SA now owns 13,328 shares of the biopharmaceutical company’s stock valued at $161,000 after buying an additional 13,036 shares during the period. 59.65% of the stock is owned by hedge funds and other institutional investors.

About Cytokinetics,

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Analyst Recommendations for Cytokinetics, (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.